According to an analysis by Bloomberg , Novartis is interested in finding a competitive Alzheimer's drug program. But it's hard to determine from the story if the pharma giant--always reluctant to detail partnering efforts or in-house strategies--has anything specific in mind.
U.K. researchers may have identified a catalytic trigger for the onset of Alzheimer's disease--a finding that could help doctors diagnose the disease earlier and potentially pave the way for a new class of drugs desperately needed to help treat the debilitating disease.
In what could be a breakthrough in drug development for the elusive Alzheimer's disease, researchers at the La Jolla, CA-based Salk Institute for Biological Studies have designed a drug that reverses memory deficits and slows progression of the disease in mice after short-term treatment.
Oxford University is marshaling money and scientists to explore massive datasets to uncover knowledge about diseases and treatments.
Researchers at Australia's national science agency believe their effort to develop a blood test to detect early-stage Alzheimer's has reached a major milestone.
Back in early 2012, a number of physicians around the U.S. began fielding some unusual requests from Alzheimer's patients for a prescription covering Targretin (bexarotene), a cancer drug sold by Eisai.
Eli Lilly plans to buy two of Seimens Healthcare Alzheimer's imaging agents, used in PET scans, all part of the drugmaker's shifting approach to treating the disease.
Undeterred by its past failures in the Alzheimer's field, Eli Lilly has invested more in research on drugs that target tangles of tau in the brains of patients with the memory-robbing disease. And the company is open to exploring combo treatments that home in on multiple culprits in the dementia, a company official tells The Wall Street Journal .
High cholesterol is often named as a risk factor for heart disease and stroke, but it may be connected to another disease as well--Alzheimer's.
Sanofi CEO Chris Viehbacher says the French drugmaker is not interested in pursuing Alzheimer's drugs until the science of the disease is better understood.